Список проголосовавших за комментарий " On The Wires<ul><li>ForeverGreen Worldwide Corporation (<strong>FVRG</strong>) announced that it will begin to transition several existing products into the global Xpress model. FrequenSea, a flag-ship product will be the first product changed to the model, as FrequenSea Pro, which will become available this spring.</li><li>TESARO, Inc. (<strong>TSRO</strong>) announced the opening of an expanded access program (EAP) in the United States for the investigational PARP inhibitor, niraparib. Through this program, niraparib is being made available for eligible women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to platinum-based chemotherapy. An EAP for niraparib in Europe is planned to open in the first half of 2017, and will be initiated on a country-by-country basis.</li><li>Callidus Software Inc. (<strong>CALD</strong>) announced a new strategic OEM agreement with SAP (<strong>SAP</strong>) to help customers sell more, faster with integrated solutions to drive sales performance, productivity and effectiveness.</li><li>AgigA Tech, a subsidiary of Cypress Semiconductor Corp. (<strong>CY</strong>), announced the production release of its AGIGARAM family of JEDEC-compliant DDR4 NVDIMM-N solutions. The solutions join AgigA's market-leading, pre-JEDEC DDR4 NVDIMM products already in volume production to provide a broad portfolio of full turnkey module products and controller solutions that adhere to the recent publicly released JEDEC standards around NVDIMM-N solutions (JESD248 and JESD245A).</li><li>Zimmer Biomet Holdings (<strong>ZBH</strong>) announced that it has implemented a leadership transition that capitalizes on the strength of the Zimmer Biomet management team. Effective January 23, 2017, Robert D. Delp will assume the position of President, Americas and join the executive leadership team of the Company. Mr. Delp previously served as Zimmer Biomet's Vice President of U.S.Sales, leading sales for the Knee, Hip, Bone Cement, Biologics, Extremities, Sports Medicine, Foot and Ankle, Surgical and Trauma categories. Stuart G. Kleopfer, following a distinguished career at Zimmer Biomet and pre-merger Biomet, has decided to retire from his position as President, Americas. Mr. Kleopfer will continue with the Company for a period of time and work closely with Mr. Delp to fully transition responsibilities.</li><li>Canadian Solar Inc. (<strong>CSIQ</strong>) announced that its wholly owned subsidiary Recurrent Energy has reached commercial operation of the adjacent 100 MWac/131 MWp Astoria and 75 MWac/100 MWp Astoria 2 solar projects located in Kern County, California.</li><li>FLIR Systems, Inc. (<strong>FLIR</strong>) announced three product families including thermal handhelds, weapon sights, and clip-ons featuring FLIR's latest compact, uncooled thermal camera core, FLIR Boson, at the 2017 Shooting Hunting Outdoor and Tactical Show in Las Vegas. All new thermal imagers allow users to detect heat and see in complete darkness, and when combined with precision optics, deliver unmatched imaging and functionality for the tactical and outdoor enthusiast markets.</li><li>MediaValet Inc. announced that Gartner (<strong>IT</strong>) has named MediaValet, in its first ever «Market Guide for Digital Asset Management,» as a Representative Vendor for mid-size to enterprise organizations looking for a SaaS-based DAM.</li><li>MakeMyTrip (<strong>MMYT</strong>), MIH Internet SEA Pte. Ltd. and MIH B2C Holdings B.V. entered into an Amendment No. 1 dated January 13, 2017, to the Transaction Agreement dated October 18, 2016, by and among MakeMyTrip, Parent and, solely for the purposes of Article XIII thereof, Guarantor. Amendment No. 1 extends the Outside Date (as defined in the Transaction Agreement) from January 16, 2017 to April 1, 2017.</li><li>Tetraphase Pharmaceuticals (<strong>TTPH</strong>) announced dosing of the first patient in IGNITE3, the Company's phase 3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem in complicated urinary tract infections.</li><li>InVivo Therapeutics Holdings Corp. (<strong>NVIV</strong>) announced that the University of New Mexico Hospital has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.</li><li>Qorvo (<strong>QRVO</strong>) received continued Trusted Source Category 1A accreditation through 2018 from the U.S. Department of Defense. </li><li>Veritable, LP. and Moelis Asset Management LP, an affiliate of Moelis & Company (<strong>MC</strong>), announced they have entered into a joint venture agreement establishing Archean Capital Partners, a private market investment platform that will provide new portfolio managers with the initial capital, advice and infrastructure necessary to launch their own funds.</li></ul>"